José Muñoz-Langa

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 103 citations · Full text

Predictive Factors of Response to Decongestive Therapy in Patients with Breast-Cancer-Related Lymphedema

Isabel Forner‐Cordero, José Muñoz-Langa, Arturo Forner‐Cordero et al. · Annals of Surgical Oncology · 2009 · 84 citations

Medicine, Predictive Factors, Breast Cancer +5

Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors

Pedro Pérez Segura, Miguel Gil‐Gil, Carmen Balañá et al. · Journal of Neuro-Oncology · 2012 · 47 citations

Leptomeningeal Metastases, Neuro-oncology, Surgical Oncology +8